A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

NCT01166490 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Neoplasms
Pancreatic Neoplasms

Interventions

DRUG: ASG-5ME

Sponsor

Seagen Inc.

Collaborators

[object Object]